|
||||||
Executive Summary Summary NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company that develops medicines for rare diseases and unmet medical needs. The company's pipeline products include NPC-09, NPC-12, NPC-15, NPC-16, NPC-17 and NPC-18. It offers products in the therapeutic areas of oncology, metabolic diseases; neurology, genetic disorders, women's health and respiratory. NobelPharma conducts research and development of drugs under categories such as orphan drugs, off-label drug, medicines used for additional efficacy, and pediatric pharmaceuticals. The company operates its branch offices in Hokkaido-Tohoku, Kanshinetu, Tokyo, Minamikanto, Tokai-Hokuriku, Kansai, Chu-Shikoku, and Kyushu, Japan. NobelPharma is headquartered in Tokyo, Japan. Nobelpharma Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios. - Business Description-A brief description of the company's operations. - Key Employees-A list of the key executives of the company. - Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors-A list of the key competitors of the company. - Key Recent Developments-A brief on recent news about the company. Reasons to buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Read More Contact Us:
Table of Contents Table of Contents 3 List of Tables 4 List of Figures 4 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10 Partnerships 10 Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10 NobelPharma Enters into Agreement with TOKUHON 11 Licensing Agreements 12 NobelPharma Enters into Licensing Agreement with Osaka University 12 NobelPharma Enters into Licensing Agreement with Kitasato University 13 NobelPharma Enters into Licensing Agreement with Savara 14 NobelPharma Enters into Licensing Agreement with Kurume University 15 NobelPharma Enters into Licensing Agreement with Serendex Pharma 16 NobelPharma Enters into Licensing Agreement with Gifu University 17 NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 18 SRI International Enters into Licensing Agreement with Nobelpharma 19 Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 20 Nobelpharma Co Ltd-Key Competitors 21 Nobelpharma Co Ltd-Key Employees 22 Nobelpharma Co Ltd-Locations And Subsidiaries 24 Head Office 24 Other Locations & Subsidiaries 24 Appendix 25 Methodology 25 About GlobalData 25 Contact Us 25 Disclaimer 25 List of Figures Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 List of Tables Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Nobelpharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8 Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10 NobelPharma Enters into Agreement with TOKUHON 11 NobelPharma Enters into Licensing Agreement with Osaka University 12 NobelPharma Enters into Licensing Agreement with Kitasato University 13 NobelPharma Enters into Licensing Agreement with Savara 14 NobelPharma Enters into Licensing Agreement with Kurume University 15 NobelPharma Enters into Licensing Agreement with Serendex Pharma 16 NobelPharma Enters into Licensing Agreement with Gifu University 17 NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 18 SRI International Enters into Licensing Agreement with Nobelpharma 19 Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 20 Nobelpharma Co Ltd, Key Competitors 21 Nobelpharma Co Ltd, Key Employees 22 Nobelpharma Co Ltd, Other Locations 24 Single User License: Site License: Corporate User License: Nobelpharma Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments. |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara" |